Ipsen: The Health Authorities of 15 European Countries Give a Collective Green Light to Azzalure(R) For the Treatment of Glabellar Lines, Paving the Way for National Marketing Authorizations

PARIS & LAUSANNE, Switzerland--(BUSINESS WIRE)--Regulatory News: Ipsen (Paris:IPN), an international innovation-driven specialty pharmaceutical Group, and Galderma, the leading pharmaceutical company in dermatology, today announced that Azzalure®, a muscle relaxant specifically developed for aesthetic use, has received the collective green light from 15 European countries’ Health Authorities for the granting of national marketing authorizations. The assessment was based on clinical trials involving more than 2,600 patients, which confirmed the safety and efficacy of Azzalure®.